Medication options when treating children and adolescents with ADHD: Interpreting the NICE guidance 2006

Archives of Disease in Childhood: Education and Practice Edition

Volumn 93, Issue 2, 2008, Pages 58-65

  Harpin, Valerie A ^a  

^a SHEFFIELD CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLONIDINE; DEXAMPHETAMINE; MEDIKINET; METHYLPHENIDATE; PLACEBO; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ADRENERGIC RECEPTOR AFFECTING AGENT; CENTRAL STIMULANT AGENT; PROPYLAMINE;

ANOREXIA; ATTENTION DEFICIT DISORDER; AUTISM; BLOOD PRESSURE; CHILD CARE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED DRUG RELEASE; COST BENEFIT ANALYSIS; DEVELOPMENTAL DISORDER; DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG METABOLISM; DRUG MISUSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPILEPSY; GASTROINTESTINAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HEALTH CARE ORGANIZATION; HEART RATE; HUMAN; IRRITABILITY; LIVER INJURY; LIVER TOXICITY; MORNING DOSAGE; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SOMNOLENCE; STOMACH PAIN; SUICIDAL IDEATION; SUSTAINED DRUG RELEASE; TACHYCARDIA; TIC; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ADOLESCENT; CHILD; PRESCHOOL CHILD;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; DEXTROAMPHETAMINE; HUMANS; METHYLPHENIDATE; PRACTICE GUIDELINES AS TOPIC; PROPYLAMINES;

EID: 42949136495     PISSN: 17430585     EISSN: 17430593     Source Type: Journal    
DOI: 10.1136/adc.2006.106864     Document Type: Review

References (71)

1. National Institute for Hearth and Clinical Excellence. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Technology appraisal 98. London: NICE, March 2006.
2. Taylor E, Sandberg S, Thorley G, et al. The epidemiology of childhood hyperactivity. London: Oxford University Press, 1991.
3. Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child 2005;90:i2-i7.
4. Varni JW, Burwinkle TM. The PedsQL™ as a patient-reported outcome in children and adolescents with attention-deficit/ hyperactivity disorder: a population-based study. Health Qual Life Outcomes 2006;4:26.
5. Preuss U, Ralston SJ, Baldursson G, et al. Study design, baseline patient characteristics and intervention in a cross-cultural framework: results from the ADORE study. Eur Child Adolesc Psychiatry 2006;15(Suppl 1):i4-i14.
6. Kadesjö B, Gillberg C. The comorbidity of ADHD in the general population of Swedish school age children. J Child Psychol Psychiatry 2001;42:487-92.
7. MTA Cooperative Group. A 14 month randomised clinical trial of treatment strategies for attention deficit hyperactivity disorder. Multimodal treatment study of children with ADHD. Arch Gen Psychiatry 1999;56:1073-86.
8. Bradley C. The behaviour of children receiving Benzedrine. Am J Psychiatry 1937;94:577-815.
9. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996;35:409-32.
10. Biederman J, Baldessarini RJ, Wright V, et al. A double blind placebo controlled study of desipramine in the treatment of ADD: 1. Efficacy. J Am Acad Child Adolesc Psychiatry 1989;28:777-84.
11. Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34:649-57.
12. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit hyperactivity disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996;35:1314-42.
13. Steingard R, Biederman J, Spencer T, et al. Comparison of Clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 1993;32:350-3.
14. Wilens TE, Biederman J, Spencer T. Clonidine for sleep disturbance associated with attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1994;33:424-6.
15. Olivera RL, Pliszka SR, Luh J, et al. An open trial of venflaxine in the treatment of attention deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 1996;6:241-509.
16. Leonard BE, McCartan D, White J, et al. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol Clin Exp 2004;19:151-80.
17. Barkley RA. A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry 1977;18:137-65.
18. Thurber S, Walker CE. Medication and hyperactivity: a meta-analysis. J Gen Psychol 1983;108:79-86.
19. Elia J, Borcherding BG, Rapoport JL, et al. Methylphenidate and dexamphetamine treatment of hyperactivity: are there true responders? Psychiatry Res 1991;36:141-55.
20. Miller A, Lee S, Raina P, et al. A review of therapies for attention deficit/hyperactivity disorder. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1999.
21. McMaster University. The treatment of attention deficit/ hyperactivity disorder. Evidence Report/Technology Assessment No 11. AHRQ Publication No. 00-E005. Rockville, MD: Agency for Healthcare Research and Quality, 1999.
22. Swanson J. Effect of stimulant medication on hyperactive children. A review. Exceptional Child 1993;60:154-62.
23. Schachar R, Tannock R. Childhood hyperactivity and psychostimulants: a review of extended treatment studies. J Child Adolesc Psychopharmacol 1993;3:81-97.
24. Greenhill LL. Stimulant medications. In: NIH Consensus Development Conference: diagnosis and treatment of attention deficit hyperactivity disorder. Bethseda: National Institute of Health, 1998:85-95.
25. Gilberg C, Melander H, von Knorring AL, et al. Long term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomised double blind placebo controlled trial. Arch Gen Psychiatry 1997;54:857-64.
26. Janssen-Cilag Ltd. Concerta XL 18 mg, Concerta XL 36 mg. Available from http://emc.medicines.org.uk (accessed 4 February 2008).
27. Swanson JM, Wigal SB, Wigal T, et al. A comparison of once daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the COMACS study). Pediatrics 2004;113:e206-16.
28. UCB Pharma Ltd. Equasym XL 10 mg, 20 mg or 30 mg capsules. Summary of product characteristics. January 2008. Available from http://emc.medicines. org.uk (accessed 4 February 2008).
29. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three times daily methylphenidate in laboratory and natural settings. Pediatrics 2001;107(6):E105.
30. Steele M, Weiss M, Swanson J, et al. A randomised controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit hyperactivity disorder. Can J Clin Pharmacol 2006;13(1):e50-e62.
31. Swanson J. Compliance with stimulants for attention-deficit/ hyperactivity disorder: issues and approaches for improvement. CNS Drugs 2003;17:117-31.
32. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention. Neuropharmacology 2002;27(5):699-711.
33. Kratochvil CJ, Bohac D, Harrington M, et al. An open-label trial of tomoxetine in pediatric attention-deficit disorder. J Child Adolesc Psychopharmacol 2001;11:167-70.
34. Spencer T, Biederman J, Heiligenstein JH, et al. An open label, dose ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001;11:251-65.
35. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder, a randomised, placebo controlled, dose response study. Pediatrics 2001;108:1-9.
36. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomised, open-label trial. J Am Acad Child Adolesc Psychiatry 2002;41:776-84.
37. Spencer T, Heiligenstein JH, Biederman J, et al. Results of two proof of concept, placebo controlled studies of atomoxetine in children with attention deficit hyperactivity disorder. J Clin Psychiatry 2002;63:1140-7.
38. Michelson D, Allen AJ, Busner J, et al. Once daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomised, placebo controlled study Am J Psychiatry 2002;159:1896-901.
39. Kelsey D, Sumner C, Casat C, et al. Once daily atomoxetine in childhood ADHD; continuous symptom relief. Poster presented the American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting, Miami, FL, October 14-19, 2003.
40. Weiss M, Tannock R, Kratochvil C, et al. Placebo controlled study of once daily atomoxetine in the school setting. Eur Neuropsychopharmacol 2003;13:S456.
41. Buitelaar JK, Danckaerts M, Gillberg C, et al. A prospective. multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur Child Adolesc Psychiatry 2004;13(4):249-57.
42. Perwien AR, Kratochvil CJ, Faries DE, et al. Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes? J Child Adolesc Psychopharmacol 2006;16(6):713-24.
43. Prasad S, Harpin V, Poole L, et al. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/ hyperactivity disorder (ADHD). Curr Med Res Opin 2007;23(2):379-94.
44. Buitelaar JK, Michelson D, Danckaerts M, et al. A randomised, double-blind study of continuation treatment for attention-deficit/ hyperactivity disorder after 1 year. Biol Psychiatry 2007;61(5): 694-9.
45. Gibson AP, Tawny BL, Patel NC, et al. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder Ann Pharmacol 2006;40:1134-41.
46. Spencer TJ, Faraone SV. Biederman J, et al. Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? J Am Acad Child Adolesc Psychiatry 2006;45(5):527-37.
47. Charach A, Figueroa M, Chen S, et al. Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry 2006;45(4):415-21.
48. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006;354:1445-8.
49. Hesdorffer DC, Ludvigsson P, Olafsson E. ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. Arch Gen Psychiatry 2004;61:731-6.
50. Gross-Tsur V, Manor I, van der Meere J. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? Pediatrics 1997;130(4):670-4.
51. Kurlan R. Methylphenidate to treat ADHD is not contraindicated in children with tics. Mov Disord 2002;17(1):5-6.
52. Goodman CR. Hepatotoxicity due to methylphenidate hydrochloride. N Y State J Med 1972;72(18):2339-40.
53. Gillberg C, Melander H, von Knorring AL, et al. Long term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomised double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997;54(9):857-64
54. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 2004;113(4):754-61.
55. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002;63(Suppl 12):50-5.
56. MHRA. Updated warning on the risk of suicidal thoughts with Strattera. Medicines and Healthcare products Regulatory Agency, 29th September 2005. http://www.mhra.gov.uk (accessed 4 February 2008).
57. James A, Lai FH, Dahl C. Attention deficit hyperactivity disorder and suicide: a review of possible associations. Acta Psychiatr Scand 2004;110:408-15.
58. Wernicke J, Chilcott KE, McAfee A. Seizure risk in patients with ADHD treated with atomoxetine. Presented at the 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, Canada, 18-23 October 2005.
59. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents and adults. Drug Saf 2003;26(10):729-40.
60. Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/ hyperactivity disorder. J Pediatr 2006;149(1):112-19.
61. McCracken JT, Salle R, Leonard HL, et al. Improvement of ADHD by atomoxetine in children with tic disorders. Abstract B28. Presented at the 50th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Florida, 14th-19th October 2003.
62. Hazell P. Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder. J Paediatr Child Health 2007;43(1-2):19-24.
63. Santosh P, Baird G, Pitvaratstian N, et al. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child Care Health Dev 2006;32(5):575-83.
64. Posey DJ, Wiegand RE, Wilkerson J, et al. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006;16(5):599-610.
65. Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006;45(10):1196-205.
66. Hack S, Chow B. Pediatric psychotropic medication compliance: a literature review and research-based suggestions for improving treatment compliance. J Child Adolesc Psychopharmacol 2001;11(1):59-67.
67. Swanson J, Greenhill L, Pelham W, et al. Initiating Concerta (OROS methylphenidate qd HCl) in children with attention-deficit hyperactivity disorder. J Clin Res 2000;3:59-76.
68. Jasinski DR, Faries D, Moore R, et al. Abuse liability of Atomoxetine in a drug abuse population. Int J Neuropsychopharmacol 2004;7(Suppl 1):S273.
69. Biederman J, Wilens T, Mick E, et al. Pharmacotherapy of attention deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999;104:e20.
70. Taylor E, Dopfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder - first upgrade. Eur Child Adolesc Psychiatry 2004;13(Suppl 1):17-30.
71. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006;15(8):476- 95.